Coherus Oncology, Inc.

Coherus Oncology, Inc.

0.46
EUR
0.00
(0.00%)
-1.07EPS
193.71MMarket Cap
Mar 15Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.15
3.8
0.81
4.54
0.03
- -
5.11
6.66
4.33
2.72
2.73
0.23
0.36
- -
Basic EPS, GAAP
-2.97
-10.64
-6.01
-3.04
-4.48
-3.22
1.29
1.85
-3.81
-3.76
-2.53
0.25
1.43
- -
Free Cash Flow per Basic Share
0.83
-3.27
-3.08
-6.18
-3.86
-2.46
0.22
2.06
-0.51
-3.13
-1.86
-0.18
-1.18
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-3.03
2.01
-0.16
0.45
0.53
-0.56
1.5
3.87
1.27
-1.74
-1.72
-1.14
0.5
- -
Tangible Book Value per Share
-3.03
1.9
-0.25
0.37
0.47
-0.62
1.44
3.83
1.22
-1.82
-2.36
-1.61
0.12
- -
Basic Weighted Avg Shares
18
8
37
42
53
65
70
71
75
78
94
115
117
142
Sales/Revenue/Turnover
3
31
30
190
2
- -
356
476
327
211
257
26
42
- -
Operating Margin (%)
-1,308.36
-207.94
-729.23
-60.98
-14,918.77
- -
30.27
32.85
-80.8
-121.72
-78.99
-756.58
-429.51
- -
Depreciation Expense
- -
1
2
3
3
3
3
3
3
4
4
5
4
- -
Net Income, GAAP
-54
-87
-223
-127
-238
-209
90
132
-287
-292
-238
29
168
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
3.17
2.55
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-1,949.65
-280.12
-743.18
-66.98
-15,306.56
- -
25.23
27.79
-87.92
-138.24
-92.48
108.03
398.43
- -
Working Capital
-8
127
91
105
117
51
228
622
437
243
144
59
65
- -
LT Debt
- -
- -
- -
100
102
103
189
414
416
476
479
268
39
- -
Total Equity
-42
67
-7
19
31
-39
105
281
98
-137
-193
-132
61
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
58.24
30.71
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
59.65
30.82
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
-909.9
- -
- -
68.49
-151.62
- -
- -
- -
- -
- -

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
2
2
- -
LT Borrowings
37
37
- -
LT Finance Leases
1
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
154
154
155
Market Capitalization
263
221
184

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
206
134
- -
Cash, Cash Equivalents & STI
167
105
- -
Accounts Receivable, Net
22
14
- -
Inventories
5
6
- -
Total Current Liabilities
134
77
- -
Payables & Accruals
115
64
- -
ST Debt
2
2
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-119.66%
-88.61%
-146.23%
Free Cash Flow
168.79%
172.6%
577.66%
Net Income, GAAP
-2.02%
8.7%
489.41%
Sales/Revenue/Turnover
- -
-14.96%
59.81%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2
10
6
54
26
2025
8
10
12
13
42
2026
12
14
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.91
-0.11
-0.09
-0.44
0.25
2025
-0.49
2.57
-0.31
-0.31
1.43
2026
-0.28
-0.13
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Denny M. Lanfear
Full Time Employees
147
Sector
Health technology
Industry
Pharmaceuticals: major
Address
333 Twin Dolphin Drive Redwood City CA United States 94065
IPO Date
Nov 12, 2014
Business
Coherus Oncology, Inc. (Nasdaq: CHRS) develops and commercializes immuno-oncology therapies for cancer patients, with a focus on next-generation combination treatments targeting the tumor microenvironment; its approved products include LOQTORZI (toripalimab-tpzi), an anti-PD-1 monoclonal antibody indicated for recurrent or metastatic nasopharyngeal carcinoma in combination with chemotherapy or as monotherapy; its pipeline features clinical-stage candidates such as casdozokitug, a first-in-class IL-27 antagonist evaluated in Phase 1/2 and Phase 2 trials for non-small cell lung cancer, hepatocellular carcinoma, and clear cell renal cell carcinoma; CHS-114, a cytolytic anti-CCR8 antibody in Phase 1 studies for advanced solid tumors including head and neck squamous cell carcinoma and gastric cancer; and CHS-1000, an anti-ILT4 antibody advancing toward first-in-human trials following FDA IND clearance in 2024. The company, founded in 2010 and headquartered in Redwood City, California, operates primarily in the United States with ongoing clinical trials across multiple solid tumor indications. In a strategic shift from biosimilars, Coherus completed the divestiture of its UDENYCA (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals in April 2025 for up to $558 million, following earlier sales of Cimerli and Humira biosimilars; it acquired Surface Oncology in September 2023, adding casdozokitug and CHS-114 to its portfolio; and continues to expand LOQTORZI through internal combinations with pipeline assets and planned external partnerships for label expansions in additional cancers.

Company News

  • Down 49.7% in 4 Weeks, Here's Why Coherus Oncology (CHRS) Looks Ripe for a Turnaround

  • Coherus Oncology: 3 Key Takeaways for Long-Term Investors

  • Coherus Oncology, Inc. (CHRS) Q3 2026 Earnings Call Transcript

  • What Coherus Oncology (CHRS) Said on Its Q3 Earnings Call

  • Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates

  • Coherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization Plan

  • Will Coherus Oncology (CHRS) Report Negative Earnings Next Week? What You Should Know

  • Coherus Oncology, Inc. (CHRS) Discusses Tagmokitug Interim Clinical Data in Esophageal Cancer Transcript

  • Coherus Oncology Reports 89% Response Rate in Early ESCC Study

  • Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development

  • Coherus to Participate in Upcoming Investor Conferences

  • Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026

  • Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026

  • Comparing Coherus Oncology (NASDAQ:CHRS) and Molecular Partners (NASDAQ:MOLN)

  • Contrasting Emergent Biosolutions (NYSE:EBS) and Coherus Oncology (NASDAQ:CHRS)

  • Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets

  • Coherus Oncology, Inc. (CHRS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

  • BlackRock Inc. Takes $16.80 Million Position in Coherus Oncology, Inc. $CHRS

  • Coherus to Participate in Upcoming Investor Conferences

  • Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights